In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; no clinically meaningful reductions in LVEF or LVEF - - On track to deliver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback